Introduction
The drive to improve the evidence base for paediatric medicines is underpinned by two major pieces of legislation established in the EU and US (EMA, 2001; FDA, 2013) . This commitment to expanding research on medicines for children is similarly supported by academic/clinical researchers, whose increased engagement in investigator-led paediatric clinical trials has given further emphasis on the importance of evidence-based practice in paediatric medicine. Meanwhile, it is widely recognised that paediatric clinical trials are challenging to deliver, and investigator-led trials can be said to be even more so due to inherent resource constraints. The trials and tribulations faced by investigators are overwhelming, and a major challenge is that of the supply of investigational drugs (Lenney et al., 2011; Whitham et al., 2009 ).
An effective and robust supply of investigational drugs and comparators, that meet the specific requirements of a study, is critical for any clinical trial. The work involved is (ICH, 1996) require compliance with applicable good manufacturing practices for all investigational drugs and comparators, with many countries legally enforcing such standards.
Poor quality products may include those with no, too little, or too much active drug, and those that degrade with toxic products or contaminants (Newton et al., 2015) . The basis of quality also encompasses the concept of bioavailability (Newton et al., 2015) . Furthermore, consideration of bioavailability must be extended to take account of drug administration, particularly in the paediatric setting. Our intrinsic clinical practice of manipulating dosage forms that are designed for adults is ill-founded as the effects of such manipulations are often poorly documented (Newton et al., 2015) . Splitting tablets can cause dose inaccuracies. Crushing or splitting some tablets, or opening capsules, destroys their release properties and can affect bioavailability. As such, the use of an age appropriate and well characterised dosage form is pertinent to assuring trial data reliability in paediatric clinical trials.
Reporting of formulation information in published paediatric clinical trials has previously been highlighted to be largely inadequate, which may, in part, reflect the lack of appreciation in the trial community of the specificities relating to pharmaceutical formulations (Pandit et al., 2010; Standing et al., 2005) . Typically appropriate formulations were not used or insufficient detail on formulations was reported to ensure that the results can be reproduced in other clinical studies and in clinical practice. The extent of the issue reported in 2005 (Standing et al., 2005) was that 37 (49%) of studies included used a paediatric formulation; only 28 (37%) publications provided adequate information for the formulation to be reproduced accurately, and 20 (26%) did not state the formulation used at all. An update to this review was published in 2010; although an improvement in reporting was anticipated a continuous trend of lack of appropriate reporting of dosage forms used was discovered (Pandit et al., 2010) . More recently a review providing more comprehensive evaluation of clinical trial needs for children has been produced, which addresses many aspects of clinical trials, not only those relating to formulations ( Van't Hoff and Offringa, 2015) .
To facilitate investigators in delivering high quality paediatric clinical trials, the National 
Results

Number of types of studies
A total of 45 investigator-led clinical trials were included in the review. Table 1 shows some details about the nature of the studies included.
Study design
In total, 20 (44%) of the studies were open-label trials and 25 (56%) of the studies were blinded. The estimated sample size of the included studies ranged from 10 to 2400 with a median value of 118.
Of the open-label studies, only 5 were single arm trials and the remaining 15 were two-arms trials comparing either different ways (e.g. timing of administration, treatment duration, high dose vs. low dose) of giving the test drug (5 studies), test drug as an addition to standard treatment (3 studies), or test drug against a different treatment (7 studies).
Blinded trial design was considered inappropriate for all 15 studies due to inherent physical differences in appearance of comparator drugs and/or the cumbersome nature of the trial for the trial participants should placebo be included in the trial design.
Of the blinded studies, 15 studies were designed so that all site personnel were blinded to treatment allocation. For the remaining 10 studies, open-label as an alternative trial design was considered to be methodologically weak, and the involvement of unblinded site personnel, either unblinded pharmacist/nurse for drug preparation/administration or independent blinded outcome assessors, was necessary to achieve blinding to assure trial robustness. Table 2 summarises the age groupings of children involved in the studies, 35 of the studies included more than one age group of children.
Age of participants
Active substances
One trial was excluded from this analysis as it was a study comparing ketogenic diet with any combinations of 20 or more different authorised antiepileptic medicinal products, and thus would have skewed the data significantly. The 44 clinical trials were investigating a total of 58 active substances. Of these, 55 active substances were listed in the British National Formulary for Children (BNFC) (December 2015 update) (Paediatric Formulary Committee, 2015) , and available as one or more authorised medicinal products. Two which were not found in the BNFC were listed in Martindale: The Complete Drug Reference (Wisher, 2012) , and were also available as one or more authorised medicinal products. The remaining one active substance was in early phase of development and had not been administered to anyone under 18 years of age.
Paediatric formulations
The pharmaceutical formulations included in the studies was of major interest in this review; in total 103 products were required to support 44 clinical trials. UK authorised products were considered suitable for use for 62 of these 103 products. Out of the 62, 29 products would require further central processing (e.g. blinding, clinical trial packaging and labelling by a third party drug manufacturer) or the involvement of unblinded personnel at investigator sites for drug administration.
The route of administration for these formulations was predominantly oral (69/103); with parenteral products being the next most common (27 in total; 20 for intravenous use and 7 for subcutaneous administration) other routes of administration included inhaled products (3); eardrops (2) and topical products to be applied to the skin (2).
In the 41 cases where a suitable UK authorised products could not be identified (see Table   3 ), bespoke manufacturing or sourcing from other European countries was deemed necessary. Sourcing of a suitable authorised product from EU was possible for 4 of the 41 products, leaving 37 products requiring bespoke manufacture. Table 4 highlights the range of pharmaceutical dosage forms that required bespoke manufacture.
Support from pharmaceutical industry
Eight out of the 14 studies received support from the pharmaceutical industry in the form of the test drug supply at no cost to the researchers. Of these, 2 test drugs were provided in a presentation which needed further labelling and packaging to meet the specificities as required by the clinical trials regulation (EMA, 2001) . Eight pharmaceutical companies who produced the study drug under investigation were approached to manufacture matching placebo products and placebo supply agreement was successfully agreed for 4 (19%) products; 3 were zero cost supplies with 1 pharmaceutical company manufacturing the placebo supply at a cost to the researcher. There was one other pharmaceutical company who provided financial support to the researcher to have bespoke placebo manufacturing to be carried out elsewhere. At the time of review, information on contract and supply agreement negotiations were available for 4 studies, and the time taken to reach an agreement was found to be a minimum of 6 months and up to 15 months in one case.
Cost of investigational drug supply
Estimated costs for investigational drug supplies were available for 19 trials. In summary, the costs on a per participant basis ranged from £95 as the minimum to £6000 as a maximum cost with the median cost per participant being £342. When these are determined as a cost per patient per day of treatment the values range from under £1 to almost £600; short studies involving multiple agents are obviously the most expensive. This range is dependent upon the need for bespoke manufacture and also the number of participants within the trial. Typical costs for the initial development and testing of a bespoke investigational drug or placebo were in the range of £30,000 -£100,000 per product. Figure 1 and 2 outline two case studies to illustrate how integrated formulation and support is required to set up paediatric clinical trials.
Case studies
Discussion
This review has highlighted that investigational drugs needed to deliver investigator-led paediatric clinical trials cannot easily be met by currently licensed medicinal products on the market. The type of study design has important implications with respect to the study drug supply; it determines the need for blinding, methods of blinding, as well as packaging configurations of study drugs needed to meet the specific requirements of individual studies. Formulation factors (e.g. appropriateness of dosage form, safety of excipients, stability), sourcing of products and trial packaging are issues which are commonly faced by researchers. Data collected and described provide evidence on the need for integrated formulation and pharmacy support from the early stages of study conception. The age range of participants within the study can affect the type and number of formulations required as this has implications for dosing strategies as well as the appropriateness of medicines for younger children. The range of ages included in the studies is aligned to previous reports where limited research is conducted in the youngest members of the population.
As expected for investigator-led clinical trials, all but one study were investigating off-label use of approved drugs. While many of these drugs, by which we mean the active drug substances, are available as authorised medicinal products, the latter may not always be in a dosage form that can be considered appropriate for paediatric clinical trials. Typically the drugs concerned are not particularly unusual in paediatric practice, however sourcing of non-UK products or bespoke manufacture of new drug dosage forms were considered more appropriate in 38% of the reviewed studies to provide age appropriate formulations for the study. This results in paediatric investigator-led trials being disadvantaged, as significant resources, both financial and time, must be made available for the development of new medicine formulations on top of other drug manufacturing and packaging activities before trials commence.
Among the different reasons, bespoke sourcing/manufacturing of investigational drugs supply was considered necessary even when the drug under investigation can be routinely 13 sourced as an unlicensed medicinal product. Unlicensed medicinal products are widely used in everyday paediatric clinical practice, and may take the form of extemporaneous products, products made under a specials licence ("Specials"), or imports. "Specials" is a UK term to describe medicines made by facilities with a Manufacturing Licence awarded by the national regulator (MHRA) using GMP standards but without Marketing Authorisation. Specials provide much greater quality assurance than extemporaneously prepared medicines, but while a "Specials" licence provides some confidence in the quality of the product it does not require a formal assessment of product safety or efficacy. The general assumption that these products are appropriate for use in clinical trials is widespread, but the fact is that this is not always the case as they do not always meet the regulatory standards on quality to assure the validity and reliability of the clinical trial results. Unlike an authorised medicinal product, which is made by a standard, reproducible process, and is well characterised in terms of its pharmaceutical and pharmacokinetic properties, this is always absent with extemporaneous products. While "Specials" have greater quality assurance in the manufacturing process than that of extemporaneously prepared products, they too often lack information on bioavailability. A study of captopril investigated the bioavailability of two commonly prescribed unlicensed liquid formulations of captopril found that both products were not bioequivalent to the licensed tablet form, or to each other, and so cannot be assumed to behave similarly in therapeutic use (Girard et al., 2013; Wan et al., 2013) . In a clinical trial context, this example illustrates the importance of understanding the formulation of the drug as clinical trial outcome may be very different depending on the product being used. It is this fundamental principle which underpins the requirements of bioequivalence as the legal basis for approving generic copies of drug products.
Furthermore, as previously highlighted by others, the reporting of complete pharmaceutical details in published clinical trial reports is essential to allow post trial application in clinical settings (Pandit et al., 2010; Standing et al., 2005) .
The practical consequence in these situations is the need to identify suitable pharmaceutical manufacturers to make the products, and the complexity of this task should not be underestimated. "Specials" manufacturers may appear to be an obvious choice; after all, they are manufacturing these products for everyday clinical use. However, not all will hold the necessary manufacturing licence to manufacture products for clinical trials use. Even for those who hold the appropriate licence, additional in vitro studies are likely to be required in order to fully characterise the pharmaceutical properties of these products.
Pharmacokinetic studies, as separate or as sub-studies, would also need to be considered to provide supporting bioavailability data (Standing et al., 2005) .
Comparative clinical trials were the most common study design in our review, which is not surprising for investigator-led trials. This brings with it the key question of blinding, specifically the ability to blind active comparators and the supply of matching placebo.
However, for reasons which have previously been described elsewhere (Wan et al., 2013) , it is not always possible to achieve either of them in a satisfactory way. The particular challenge lies in the fact that liquid dosage form, as demonstrated in this data and previous studies, is the most common formulation used in paediatric clinical trials (Pandit et al., 2010; Standing et al., 2005) . While this offers dosing flexibility to accommodate weight-based dosing, the pharmaceutical aspects of liquid formulations lead to complex blinding challenges.
Support from pharmaceutical companies can greatly facilitate the delivery of paediatric investigator-led clinical trials. After all, they would have manufactured the investigational drug and placebo for their own marketing authorisation trials, and have all the required technical data on the manufacturing and analytical methods to support clinical trial application. However, the unfortunate reality is that for many pharmaceutical companies, manufacturing on the comparatively limited quantity for independent researchers is simply too difficult to accommodate. Even if supply can be agreed, it is also important to bear in mind that contract negotiations can be lengthy; the divergent needs of the pharmaceutical industry and academic researchers often gave rise to contentious issues surrounding investigational drugs supply and trial protocol designs, which could result in long delays as reported by us and others (Lenney et al., 2011; Whitham et al., 2009 ).
On the basis of the issues described, it is essential that investigators are supported in sourcing appropriate products for use in paediatric clinical trials. Those involved in the design and development of investigator-led clinical trials are typically unaware of the different factors relating to investigational drugs supply (Girard et al., 2013) To the best of our knowledge, this pharmacy and formulations support provided by the CRN: Children is unique, and such collective review of paediatric investigator-led clinical trials has not been published previously. Those with formulations and research expertise are able to intrinsically examine pharmaceutical aspects along with trial methodology and implementation to enable studies to be delivered using high quality medicinal products. The unique and valued role of pharmacists in multidisciplinary teams has been highlighted in several clinical areas including optimisation of pharmacy content in clinical cancer research protocols (Debruyne et al., 2015; Fairbanks et al., 2007) . However, their role in the design and planning of clinical trials can be overlooked, and yet this study demonstrates their value in maximising the likelihood of success of paediatric clinical trials. Informal feedback from investigators to the Pharmacy and Formulations team has been very positive with researchers echoing comments made in previous publications (Lenney et al., 2011; Whitham et al., 2009) where the value of involving pharmacy and formulations expertise early in the trial is acknowledged to be imperative to success.
Conclusions
Despite representing a fundamental step towards evidence-based paediatric practice, the delivery of investigator-led clinical trials in children poses important challenges in relation to investigational drugs supply, partly due to the historical lack of authorised age appropriate formulations for children. The complexity of these challenges is greatly influenced by study designs, which in turn may be limited by the availability of suitable formulations. In undertaking the supply arrangement, considerations should be given to formulation factors, regulatory requirements, trial logistics, as well as the cost of research. Notwithstanding, our experience demonstrates that the majority of these challenges can be appropriately addressed with early pharmacy and formulation experts engagement.
paediatrics, but if the quality of the investigational drugs and comparators being used is not assured, these clinical trials may put patients at risk, conclude with erroneous results, and thus be a major waste of time and public investment. The development of awareness and access to pharmacy and formulations support will aid in the development and delivery of robust high-quality clinical trials in children.
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